|
1
|
Ahmed R, Khan NA, Waseem M and Khan ZJ:
Holistic approach in the management of depression: A Review. J
Integ Comm Health. 6:10–14. 2017.
|
|
2
|
World Health Organization (WHO):
Depression and other common mental disorders. Global Health
Estimates (GHE), Geneva, Switzerland pp24, 2017.
|
|
3
|
Siu AL, Bibbins-Domingo K, Grossman DC,
Baumann LC, Davidson KW, Ebell M, García FA, Gillman M, Herzstein
J, Kemper AR, et al: US Preventive Services Task Force (USPSTF).
Screening for depression in adults: US Preventive Services Task
Force recommendation statement. JAMA. 315:380–387. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Duman RS, Aghajanian GK, Sanacora G and
Krystal JH: Synaptic plasticity and depression: New insights from
stress and rapid-acting antidepressants. Nat Med. 22:238–249.
2016.PubMed/NCBI View
Article : Google Scholar
|
|
5
|
Su CL, Su CW, Hsiao YH and Gean PW:
Epigenetic regulation of BDNF in the learned helplessness-induced
animal model of depression. J Psychiatr Res. 76:101–110.
2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Zhou C, Zhong J, Zou B, Fang L, Chen J,
Deng X, Zhang L, Zhao X, Qu Z, Lei Y, et al: Meta-analyses of
comparative efficacy of antidepressant medications on peripheral
BDNF concentration in patients with depression. PLoS One.
12(e0172270)2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
De Vry J, Vanmierlo T, Martínez-Martínez
P, Losen M, Temel Y, Boere J, Kenis G, Steckler T, Steinbusch HWM,
Baets M, et al: TrkB in the hippocampus and nucleus accumbens
differentially modulates depression-like behavior in mice. Behav
Brain Res. 296:15–25. 2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Lapchak PA, Araujo DM and Hefti F: BDNF
and trkB mRNA expression in the rat hippocampus following
entorhinal cortex lesions. Neuroreport. 4:191–194. 1993.PubMed/NCBI View Article : Google Scholar
|
|
9
|
David DJ, Tritschler L, Guilloux JP,
Gardier AM, Sanchez C and Gaillard R: Pharmacological properties of
vortioxetine and its pre-clinical consequences. Encephale.
42(1S12-1S23)2016.PubMed/NCBI View Article : Google Scholar : (In French).
|
|
10
|
Frampton JE: Vortioxetine: A review in
cognitive dysfunction in depression. Drugs. 76:1675–1682.
2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Thase ME, Danchenko N, Brignone M, Florea
I, Diamand F, Jacobsen PL and Vieta E: Comparative evaluation of
vortioxetine as a switch therapy in patients with major depressive
disorder. Eur Neuropsychopharmacol. 27:773–781. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Baune BT, Sluth LB and Olsen CK: The
effects of vortioxetine on cognitive performance in working
patients with major depressive disorder: A short-term, randomized,
double-blind, exploratory study. J Affect Disord. 229:421–428.
2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Nishimura A, Aritomi Y, Sasai K, Kitagawa
T and Maha-bleshwarkar AR: Randomized, double-blind,
placebo-controlled 8-week trial of the efficacy, safety, and
tolerability of 5, 10, and 20 mg/day vortioxetine in adults with
major depressive disorder. Psychiatry Clin Neurosci. 72:64–72.
2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Connolly KR and Thase ME: Vortioxetine: A
new treatment for major depressive disorder. Expert Opin
Pharmacother. 17:421–431. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Harrison JE, Lophaven S and Olsen CK:
Which cognitive domains are improved by treatment with
vortioxetine? Int J Neuropsychopharmacol.
19(pyw054)2016.10.1093/ijnp/pyw054. PubMed/NCBI View Article : Google Scholar
|
|
16
|
Lee B and Lee H: Systemic administration
of curcumin affect anxiety-related behaviors in a rat model of
posttraumatic stress disorder via activation of serotonergic
systems. Evid Based Complement Alternat Med. 2018(9041309)2018.
View Article : Google Scholar : https://doi.org/10.1155/2018/9041309.
|
|
17
|
Pooley AE, Benjamin RC, Sreedhar S, Eagle
AL, Robison AJ, Mazei-Robison MS, Breedlove SM and Jordan CL: Sex
differences in the traumatic stress response: The role of adult
gonadal hormones. Biol Sex Differ. 9(32)2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Hatherall L, Sánchez C and Morilak DA:
Chronic vortioxetine treatment reduces exaggerated expression of
conditioned fear memory and restores active coping behavior in
chronically stressed rats. Int J Neuropsychopharmacol. 20:316–323.
2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Żmudzka E, Sałaciak K, Sapa J and Pytka K:
Serotonin receptors in depression and anxiety: Insights from animal
studies. Life Sci. 210:106–124. 2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Yohn CN, Gergues MM and Samuels BA: The
role of 5-HT receptors in depression. Mol Brain.
10(28)2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Fisher PM, Ozenne B, Svarer C, Adamsen D,
Lehel S, Baaré WF, Jensen PS and Knudsen GM: BDNF val66met
association with serotonin transporter binding in healthy humans.
Transl Psychiatry. 7(e1029)2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Katona CL and Katona CP: New generation
multi-modal antidepressants: Focus on vortioxetine for major
depressive disorder. Neuropsychiatr Dis Treat. 10:349–354.
2014.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Mahableshwarkar AR, Zajecka J, Jacobson W,
Chen Y and Keefe RS: A randomized, placebo-controlled,
active-reference, double-blind, flexible-dose study of the efficacy
of vortioxetine on cognitive function in major depressive disorder.
Neuropsychopharmacology. 40:2025–2037. 2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Talebian A, Robinson-Brookes K and Meakin
SO: TrkB regulates N-Methyl-D-aspartate receptor signaling by
uncoupling and recruiting the brain-specific guanine nucleotide
exchange factor, RasGrf1. J Mol Neurosci. 67:97–110.
2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Fukuda M, Takatori A, Nakamura Y, Suganami
A, Hoshino T, Tamura Y and Nakagawara A: Effects of novel small
compounds targeting TrkB on neuronal cell survival and
depression-like behavior. Neurochem Int. 97:42–48. 2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Kozono N, Ohtani A and Shiga T: Roles of
the serotonin 5-HT4 receptor in dendrite formation of the rat
hippocampal neurons in vitro. Brain Res. 1655:114–121. 2017.
View Article : Google Scholar
|
|
27
|
Rumajogee P, Madeira A, Vergé D, Hamon M
and Miquel MC: Up-regulation of the neuronal serotoninergic
phenotype in vitro: BDNF and cAMP share Trk B-dependent mechanisms.
J Neurochem. 83:1525–1528. 2002.PubMed/NCBI View Article : Google Scholar
|
|
28
|
McMorris T: Developing the catecholamines
hypothesis for the acute exercise-cognition interaction in humans:
Lessons from animal studies. Physiol Behav. 165:291–299.
2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Sagud M, Nikolac Perkovic M, Vuksan-Cusa
B, Maravic A, Svob Strac D, Mihaljevic Peles A, Zivkovic M, Kusevic
Z and Pivac N: A prospective, longitudinal study of platelet
serotonin and plasma brain-derived neurotrophic factor
concentrations in major depression: Effects of vortioxetine
treatment. Psychopharmacology (Berl). 233:3259–3267.
2016.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Lu Y, Ho CS, McIntyre RS, Wang W and Ho
RC: Effects of vortioxetine and fluoxetine on the level of Brain
Derived Neurotrophic Factors (BDNF) in the hippocampus of chronic
unpredictable mild stress-induced depressive rats. Brain Res Bull.
142:1–7. 2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Thase ME, Mahableshwarkar AR, Dragheim M,
Loft H and Vieta E: A meta-analysis of randomized,
placebo-controlled trials of vortioxetine for the treatment of
major depressive disorder in adults. Eur Neuropsychopharmacol.
26:979–993. 2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Li Y, Pehrson AL, Oosting RS, Gulinello M,
Olivier B and Sanchez C: A study of time- and sex-dependent effects
of vortioxetine on rat sexual behavior: Possible roles of direct
receptor modulation. Neuropharmacology. 121:89–99. 2017.PubMed/NCBI View Article : Google Scholar
|
|
33
|
McIntyre RS: The role of new
antidepressants in clinical practice in Canada: A brief review of
vortioxetine, levomilnacipran ER, and vilazodone. Neuropsychiatr
Dis Treat. 13:2913–2919. 2017.PubMed/NCBI View Article : Google Scholar
|
